eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

BACKGROUND: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors of bevacizumab efficacy have not yet been identified. We analyzed vascular endothelial growth factor (VEGF) and endothelial nit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Transl Med
Main Authors: Ulivi, Paola, Scarpi, Emanuela, Passardi, Alessandro, Marisi, Giorgia, Calistri, Daniele, Zoli, Wainer, Del Re, Marzia, Frassineti, Giovanni Luca, Tassinari, Davide, Tamberi, Stefano, Vertogen, Bernadette, Amadori, Dino
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531503/
https://ncbi.nlm.nih.gov/pubmed/26259598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0619-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki